What Distaclor Treats: Main Uses and Benefits

Distaclor is relevant in the management of bacterial infections across several key therapeutic domains. Its use is applicable within clinical settings that involve acute or disruptive symptom patterns, and it is relevant when supportive symptom management is appropriate. The medication supports symptomatic relief by helping to clear the underlying infection responsible for symptoms related to localized discomfort and systemic imbalance.

Distaclor is commonly used for infections affecting the ear, nose, and throat (such as otitis media, sinusitis, and pharyngitis), the lower respiratory tract (pneumonia and acute bronchitis exacerbations), the genitourinary system (UTIs), and the skin and soft tissues. The medication assists with maintaining functional stability by supporting the clearance of the bacterial source that drives symptoms such as fever, cough, or localized pain.

“It contributes to easing the overall symptom load by assisting in the clearance of the infection that often leads to persistent discomfort and disruption of daily stability.”

Quick Fact: Relief for Acute Infections
The drug is commonly used to manage the symptom clusters associated with acute episodes in both adults and pediatric patients.

Regulatory References

1. NIH MedlinePlus overview of Cefaclor

The eligibility for using Distaclor (Cefaclor) is governed by strict regulatory documentation defining contraindications and conditions for restricted use.

Absolute Contraindications

Category	Official Regulatory Statement
Hypersensitivity	Contraindicated in patients with a known allergy to Cefaclor or the cephalosporin class of antibiotics.
Age Exclusion	Safety and efficacy have not been established for use in infants less than one month of age.

---

Conditional Use and Restrictions

Category	Official Regulatory Statement
Penicillin Allergy	Caution must be exercised in patients with a history of penicillin sensitivity due to the documented risk of cross-hypersensitivity.
Renal Impairment	Caution is advised in the presence of markedly impaired renal function; however, dosage adjustments are usually not required.
GI Disease	Prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.
Pregnancy/Lactation	Pregnancy: Use only if clearly needed. Lactation: Caution is advised as small amounts are detected in breast milk and the effect on the nursing infant is not known.

---

Official regulatory documents define absolute prohibitions based on patient allergies to Cefaclor or cephalosporins. They establish a clear age exclusion for infants under one month, where use is not established. Furthermore, they mandate caution for specific co-morbidities like impaired renal function and colitis and require conditional use during pregnancy and lactation.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Distaclor (Cefaclor) through effects on drug exposure, absorption timing, and pharmacodynamic outcomes.

Documented Interaction Patterns

Interaction Type	Interacting Substance	Official Outcome / Restriction
Renal Clearance	Probenecid	Increases Cefaclor serum concentration and prolongs half-life due to inhibition of renal tubular secretion.
Coagulation Risk	Oral Anticoagulants (e.g., Warfarin)	Associated with increased prothrombin time; requires regular monitoring.
Absorption Timing	Aluminum- or Magnesium-containing Antacids	Diminishes the extent of Cefaclor absorption. May require time separation.

Additional Official Interaction Statements

Co-administration with probenecid is documented to increase the overall exposure to Cefaclor. Use with oral anticoagulants like warfarin is linked to an enhanced anticoagulant effect, which manifests as an increased prothrombin time. Therefore, official guidance requires appropriate monitoring of coagulation status. Specific Cefaclor formulations may require that aluminum- or magnesium-containing antacids be administered with a separation of at least one hour to prevent interference with Cefaclor uptake. The combination of Cefaclor with aminoglycosides may increase the risk of nephrotoxicity.

Furthermore, Cefaclor can cause a false-positive reaction for glucose in urine tests utilizing copper sulfate solutions.

Blocking Bacterial Cell Wall Synthesis

Distaclor (cefaclor) works by acting as an irreversible inhibitor of specific bacterial enzymes known as Penicillin-Binding Proteins (PBPs), which are essential for synthesizing the rigid, protective wall that surrounds bacteria. The drug achieves this by binding covalently to the active site of the PBPs, blocking their function in the cell wall assembly line. This interaction prevents the essential final step of construction: the peptidoglycan cross-linking.

---

Mechanistic Cascade of Cellular Destruction

By interfering with the essential cell wall assembly process, the mechanism creates a severe structural defect. This failure causes the internal osmotic pressure within the bacterial cell to exceed the wall's capacity, leading to a loss of structural integrity and eventual cell rupture, a process known as lysis. This bactericidal effect on the individual cell structures is correlated with a reduction in the population count of the susceptible bacterial species.

Distaclor is administered exclusively through the oral route across all its approved dosage forms, including immediate-release (IR) capsules, oral suspension, and extended-release (ER) tablets. The core adult regimen for IR forms is 250 mg every 8 hours (three times daily), though this dose may be increased up to 500 mg every 8 hours for managing more severe infections. This standardized frequency defines the typical administration schedule for most IR users.

The required timing of intake is dependent on the formulation: IR capsules and the reconstituted suspension may be taken with or without food, as total drug absorption remains consistent. Conversely, ER tablets must be administered with meals or within one hour of eating to ensure effective drug uptake. These tablets must be swallowed whole and cannot be split, crushed, or chewed, which preserves the controlled release of the medication.

For pediatric use, Cefaclor is established for patients 1 month of age and older, with dosing calculated based on weight, typically ranging from 20 mg/kg/day to 40 mg/kg/day in divided doses. The typical duration of therapy is 7 to 10 days, with a minimum course of 10 days for infections caused by streptococci. Patients undergoing hemodialysis require a specific loading dose administered prior to the procedure, followed by a tailored maintenance dose in the interdialytic period.

Research Evidence / Overview of Studies

Efficacy and Mechanism of Action

Studies investigated the initial goals of treatment and the duration of symptomatic change for condition X (Cefaclor is the active ingredient in Distaclor). Research explored the potential mechanism of action, which was investigated in laboratory studies. This proposed mechanism is related to the inhibition of bacterial cell-wall synthesis, and this finding was primarily studied in laboratory models and early-phase clinical trials.

• Clinical Endpoints: Key studies examined changes in measures of infection severity and flare-up frequency, specifically in respiratory, skin, and urinary tract infections. The primary clinical trials were randomized, double-blind, and placebo-controlled. Further analysis assessed the impact on patient-reported quality of life (QoL) metrics.
• Time to Response: Data analyzed the onset of symptomatic change, with first measurement points occurring within 24 to 72 hours of the initial dose. Trial protocols typically measured the full extent of change after 7 to 14 days of continuous use, depending on the infection type.

---

Safety and Tolerability Profile

Trials assessed the safety profile in adult and pediatric patients. The most frequently reported adverse events in clinical trials were mild to moderate gastrointestinal (GI) discomfort and headache.

• Serious Adverse Events (SAEs): The rate of SAEs was comparable between the treatment group and the placebo group in the initial studies. Reported safety findings included data related to changes in liver enzyme levels and the possibility of hypersensitivity reactions, such as skin rash.
• Drug-Drug Interactions: Preliminary non-clinical studies examined potential interactions with commonly co-administered medications, including compounds that may reduce absorption (e.g., antacids) or increase plasma concentration (e.g., probenecid).

---

Subgroup and Comparative Research

A comparative study evaluated the outcomes of the drug against other established antibiotic protocols, often belonging to the macrolide or fluoroquinolone classes. This research focused on whether the different treatments resulted in statistically significant differences in the primary outcome measure.

• Pharmacokinetic Studies: Long-term data from trials explored outcomes for difficult-to-treat subsets of infection. A pharmacokinetic study measured systemic exposure, and findings suggested a relationship between administration timing and absorption metrics.

Key Studies & References

1. Pharmacokinetics and safety of the two oral cefaclor formulations in healthy chinese subjects in the fasting and postprandial states

Common questions about Distaclor (FAQ)

---

Q: Is Distaclor the same as penicillin?

A: Distaclor (cefaclor) is an antibiotic in the cephalosporin class, which is different from the penicillin class. However, both belong to the larger group of beta-lactam antibiotics. Official documents indicate that the potential for cross-hypersensitivity has been documented between these classes.

Q: Is Distaclor considered a strong antibiotic?

A: Cefaclor is classified as a second-generation cephalosporin. Official information indicates it has an expanded spectrum of activity against certain types of bacteria. It is often selected for infections that require this specific profile of expanded coverage.

Q: Why is Distaclor sometimes prescribed for ear infections?

A: Official regulatory documents explicitly list otitis media (middle ear infections) as one of the therapeutic indications for Distaclor. It is used when the infection is caused by specific susceptible bacterial strains, such as S. pneumoniae and H. influenzae.

Q: What kind of common food or drinks might interact with Distaclor?

A: For the Immediate Release (IR) forms of Cefaclor, the medication can typically be taken with or without food. While specific common foods or beverages are not listed as mandatory to avoid in regulatory documents (outside of certain antacids), patients should generally continue a normal diet.

Q: Is Distaclor used to treat viral infections?

A: Distaclor is defined as an antibiotic designed to fight bacteria. Official warnings state that using the drug in the absence of a bacterial infection is unlikely to provide benefit and may increase the risk of developing drug resistance.

Q: Is Distaclor available over the counter in some places?

A: According to official product information, Distaclor (Cefaclor) is classified as a synthetic prescription medicine. Therefore, it is typically available only through a licensed practitioner and dispensed by a pharmacist.

Q: Why might Distaclor be preferred over other antibiotics for certain conditions?

A: The selection of Distaclor is based on its antibacterial spectrum. As a second-generation cephalosporin, it has an expanded range of coverage against certain bacteria. Official information indicates that this spectrum profile is the basis for its use when specific target pathogens are identified.

Q: What is the difference between Distaclor and Cefaclor?

A: Cefaclor is the active ingredient and the generic name of the medicine. Distaclor is one of the brand names under which the product containing Cefaclor is commercially marketed.

Q: Is the side effect of diarrhea from Distaclor serious?

A: Common diarrhea is listed as one of the more frequently reported side effects. However, regulatory warnings also note the potential for a rare, severe intestinal condition called Pseudomembranous Colitis, which causes serious diarrhea and can range in severity from mild to life-threatening.

Q: How should Distaclor be handled if a person has diabetes?

A: Official information indicates that Cefaclor may interfere with certain laboratory tests. Specifically, it can cause a false-positive reaction when checking for glucose in the urine using copper sulfate solutions. This potential diagnostic interference should be noted.

Q: What makes Distaclor different from first-generation cephalosporins?

A: Distaclor is defined as a second-generation cephalosporin. This means it has an expanded spectrum of activity, particularly against certain Gram-negative bacteria (like H. influenzae), compared to first-generation cephalosporins.

Q: Does research support the use of Distaclor in chronic infections?

A: Yes. Regulatory documentation indicates that Cefaclor is used to treat acute bacterial exacerbations of chronic bronchitis. Research has also found it effective in managing certain chronic urinary tract infections.

Q: Can Distaclor cause tiredness or fatigue?

A: Official information reports that adverse reactions under the Central Nervous System (CNS) category mention somnolence (drowsiness), though the causal relationship is uncertain. Unusual tiredness is also listed as a symptom that may be associated with other potential safety issues.

Q: What should I do if I forget to take Distaclor?

A: Official regulatory documents and patient information contain specific instructions for what to do in the event of a missed dose. This guidance outlines the timing for taking a dose upon remembering and when it is necessary to skip the missed dose and continue the regular schedule.

Q: How long does Distaclor stay in your system after the last dose?

A: Cefaclor is known to have a short half-life, which is the time it takes for the concentration of the drug in the body to decrease by half. For subjects with normal kidney function, the half-life is typically short, ranging from 0.6 to 0.9 hours.

Q: Can older adults use Distaclor safely?

A: Official dosing guidelines for adults include the elderly, and the documentation states that specific dosage adjustments are not typically required based on age alone. However, official caution is advised in the presence of impaired kidney function.

Q: Does Distaclor interact with common pain relievers like ibuprofen?

A: While specific interactions with Ibuprofen are not detailed in the core warnings, regulatory documents indicate a potential risk of increased nephrotoxicity (kidney damage) when Cefaclor is combined with certain other drugs belonging to the Non-Steroidal Anti-inflammatory Drug (NSAID) class.

Q: Can Distaclor cause yeast infections?

A: Yes. Adverse effects considered related to therapy include moniliasis or vaginitis (fungal/yeast infections), with reports of both oral thrush and vaginal yeast infections in official product information.

Q: Why is it important to finish the full course of Distaclor?

A: Official patient information describes that completing the full prescribed course is important to support the successful elimination of the bacterial infection. Stopping treatment prematurely increases the potential risk that the infection may return and that the remaining bacteria could develop antibiotic resistance.

Q: Can Distaclor affect blood sugar levels?

A: Cefaclor is not documented to directly affect blood sugar levels. However, it can cause a false-positive reaction for glucose in urine tests using specific solutions, which may interfere with diabetic monitoring.

Q: Is it possible to develop a resistance to Distaclor?

A: Yes. Regulatory warnings highlight that improper use, such as prescribing it for non-bacterial infections or failing to complete the full course of treatment, increases the risk of the targeted bacteria developing resistance to the antibiotic.

Q: Why do some forms of Distaclor need to be shaken before use?

A: Official patient information states that the liquid form (oral suspension) is to be shaken well before use. This administration step is intended to ensure the medication is mixed evenly throughout the liquid, which supports the consistent delivery of the prescribed dose.

Q: What happens if I stop taking Distaclor too early?

A: Official patient information states that stopping the medicine too early can result in the infection not clearing completely, or it may allow your symptoms to return. This action also increases the risk of the remaining bacteria becoming resistant to the antibiotic.

How to Store and Dispose of Distaclor?

The official storage conditions for Distaclor (Cefaclor) are dependent on the form and are designed to maintain stability.

Storage Requirements

• Solid Forms (Capsules/Tablets): Store at a maximum temperature of 25 °C (or controlled room temperature) in the original package to protect from light and moisture.
• Reconstituted Oral Suspension: Must be stored in a refrigerator (2 °C-8 °C) and must not be frozen.
• Stability: The refrigerated liquid suspension is stable for 14 days after reconstitution; any unused portion must be discarded after this period.

Safety and Disposal

The medicine must be kept out of the sight and reach of children at all times.

Expired or unused Distaclor must not be thrown away via wastewater or household waste. Disposal must be performed in accordance with local requirements by consulting a pharmacist.